News coverage about Voyager Therapeutics (NASDAQ:VYGR) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Voyager Therapeutics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.0848195614093 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Voyager Therapeutics, Inc. (VYGR) Earns “Hold” Rating from Chardan Capital (americanbankingnews.com)
- Critical Comparison: Voyager Therapeutics (VYGR) versus Merrimack Pharmaceuticals (MACK) (americanbankingnews.com)
- Here's Why Voyager Therapeutics Gained as Much as 24.9% Today (finance.yahoo.com)
- Insider Selling: Voyager Therapeutics, Inc. (VYGR) Insider Sells 5,490 Shares of Stock (americanbankingnews.com)
- Novavax (NVAX) versus Voyager Therapeutics (VYGR) Head-To-Head Review (americanbankingnews.com)
Shares of Voyager Therapeutics (NASDAQ VYGR) opened at 14.32 on Wednesday. The stock has a 50 day moving average of $9.57 and a 200-day moving average of $10.30. The firm’s market capitalization is $385.25 million. Voyager Therapeutics has a one year low of $8.10 and a one year high of $18.25.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.11). The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. On average, equities analysts anticipate that Voyager Therapeutics will post ($2.84) earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on VYGR shares. Chardan Capital reissued a “hold” rating on shares of Voyager Therapeutics in a report on Sunday. ValuEngine upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Stifel Nicolaus restated a “buy” rating and set a $33.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. BidaskClub upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Zacks Investment Research downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $23.43.
In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the transaction, the insider now owns 17,157 shares in the company, valued at $171,570. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is currently owned by corporate insiders.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.